Travere Therapeutic
TVTX
53.44
-2.54
-4.54%
Travere Therapeutic
US · TVTX
#2056 by market cap
Listed 1970
53.44
-2.54
-4.54%
Live - 5344 symbols - heartbeat 544s ago
· 2026-10-08 07:24
Pre-market
53.30
-0.26%
After-hours
53.44
0.00%
- Market cap
- 5.04B
- P/E (TTM)i
- -116.17
- P/Bi
- 205.54
- EPSi
- -0.29
- Div yieldi
- 0.00%
- 52W posi
- 67%
Reader sentiment
Are you bullish or bearish on TVTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.78, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +110.45% YoY
Margins
- Gross margin
- 97.89%
- Operating margin
- -12.80%
- Net margin
- -5.21%
Key ratios & quality
- Enterprise valuei
- 5.03B
- Altman Z-Scorei
- 3.78
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 164.25M | 175.34M | 198.32M | 131.84M | 109.46M | 145.24M | 233.18M | 490.73M |
| Gross profit | 158.72M | 170.10M | 192.20M | 128.02M | 105.04M | 133.79M | 225.43M | 480.39M |
| Selling & admin expenses | 103.65M | 128.95M | 135.80M | 126.28M | 197.52M | 265.54M | 264.12M | 337.20M |
| Research & development | 123.76M | 140.96M | 131.77M | 201.16M | 227.33M | 244.99M | 282.70M | 206.01M |
| Operating profit | -68.69M | -99.81M | -75.38M | -199.43M | -319.81M | -376.74M | -321.39M | -62.82M |
| Pretax profit | -101.87M | -146.45M | -188.79M | -216.88M | -331.16M | -376.11M | -320.51M | -49.27M |
| Tax | 811.00K | -21.00K | -19.36M | 409.00K | 313.00K | 223.00K | 120.00K | 988.00K |
| Net profit | -102.68M | -146.43M | -169.43M | -180.09M | -278.48M | -111.40M | -321.55M | -25.55M |
| Basic EPS | -3 | -3 | -4 | -3 | -4 | -2 | -4 | 0 |
| Diluted EPS | -2.54 | -3.46 | -3.56 | -3.01 | -4.37 | -1.50 | -4.08 | -0.29 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 81.73M | 114.45M | 164.86M | 129.69M | 127.20M | 169.58M |
| Gross profit | 64.63M | 99.29M | 163.27M | 127.14M | 100.43M | 160.35M |
| Selling & admin expenses | 60.41M | 62.58M | 86.45M | 101.69M | 80.25M | 96.11M |
| Research & development | 46.89M | 49.36M | 51.89M | 57.87M | 57.09M | 60.28M |
| Operating profit | -42.67M | -12.65M | 24.93M | -32.43M | -36.92M | 3.95M |
| Pretax profit | -41.19M | -12.74M | 25.71M | -21.07M | -36.72M | -35.00M |
| Tax | 39.00K | 20.00K | 8.00K | 921.00K | -120.00K | -204.00K |
| Net profit | -41.23M | -12.76M | 25.71M | 2.73M | -37.10M | -34.80M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.47 | -0.14 | 0.28 | 0.03 | -0.40 | -0.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 495.68M | 429.06M | 410.41M | 582.83M | 486.44M | 616.78M | 416.70M | 437.57M |
| Cash & ST investments | 471.54M | 398.52M | 361.59M | 552.88M | 450.25M | 566.85M | 370.70M | 322.80M |
| Inventory | 5.62M | 6.08M | 7.61M | 7.31M | 4.52M | 9.41M | 6.20M | 5.88M |
| Total assets | 709.16M | 604.80M | 607.44M | 776.63M | 672.59M | 788.91M | 594.13M | 605.19M |
| Total current liabilities | 104.62M | 95.45M | 92.66M | 124.09M | 142.16M | 177.91M | 200.75M | 159.90M |
| Short-term debt | 22.46M | -- | 357.00K | 3.91M | 4.43M | 4.91M | 74.08M | 5.88M |
| Long-term debt | 195.09M | 204.86M | 215.34M | 226.58M | 375.55M | 377.26M | 310.31M | 311.72M |
| Total liabilities | 390,907,000.00 | 383,604,000.00 | 396,226,000.00 | 474,521,000.00 | 629,734,000.00 | 588,103,000.00 | 535,048,000.00 | 490,363,000.00 |
| Total equity | 318.25M | 221.20M | 211.21M | 302.11M | 42.85M | 200.81M | 59.08M | 114.83M |
| Retained earnings | -270.02M | -416.44M | -585.88M | -765.97M | -1.01B | -1.13B | -1.45B | -1.47B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 374.17M | 379.57M | 371.11M | 437.57M | 392.68M | 615.14M |
| Cash & ST investments | 322.24M | 319.54M | 254.53M | 322.80M | 264.68M | 489.18M |
| Inventory | 3.93M | 4.09M | 5.55M | 5.88M | 6.36M | 7.84M |
| Total assets | 548.80M | 555.31M | 538.58M | 605.19M | 555.19M | 799.36M |
| Total current liabilities | 182.46M | 189.54M | 135.07M | 159.90M | 125.44M | 152.03M |
| Short-term debt | 74.22M | 74.43M | 5.73M | 5.88M | 6.02M | 6.16M |
| Long-term debt | 310.66M | 311.02M | 311.37M | 311.72M | 312.08M | 602.78M |
| Total liabilities | 515,976,000.00 | 522,562,000.00 | 465,017,000.00 | 490,363,000.00 | 456,460,000.00 | 774,838,000.00 |
| Total equity | 32.82M | 32.75M | 73.56M | 114.83M | 98.73M | 24.52M |
| Retained earnings | -1.49B | -1.50B | -1.48B | -1.47B | -1.51B | -1.54B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -24.96M | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M | -237.48M | 37.78M |
| Depreciation & amortization | 18.67M | 20.41M | 24.58M | 12.75M | 20.72M | 38.53M | 43.56M | 60.74M |
| Free cash flow | -44.66M | -73.78M | -162.59M | -38.94M | -214.66M | -321.61M | -338.69M | -20.37M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 131.52M | 224.93M | 19.55M | 191.20M | 134.74M | 0 |
| Ending cash balance | 102.87M | 62.44M | 84.77M | 165.75M | 61.69M | 58.18M | 58.54M | 93.04M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -42.19M | 4.98M | 14.32M | 60.68M | -40.37M | 58.07M |
| Depreciation & amortization | 12.80M | 14.02M | 15.79M | 18.14M | 25.21M | 4.23M |
| Free cash flow | -53.98M | -7.10M | -1.11M | 41.81M | -62.54M | 37.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 61.90M | 75.15M | 110.93M | 93.04M | 78.36M | 117.74M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -33.59 | -54.29 | -78.37 | -70.17 | -161.46 | -91.44 | -247.45 | -29.38 |
| ROA %i | -16.70 | -22.29 | -27.95 | -26.02 | -38.43 | -15.24 | -46.50 | -4.26 |
| ROIC %i | -22.21 | -29.31 | -36.79 | -33.55 | -54.13 | -22.66 | -61.30 | -6.00 |
| 5-year avg ROE %i | -- | -6.85 | -40.38 | -51.26 | -79.57 | -91.14 | -129.78 | -119.98 |
| EBIT margin %i | -56.05 | -72.79 | -85.59 | -70.13 | -125.88 | -251.16 | -132.66 | -7.85 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.74 | 4.50 | 4.43 | 4.70 | 3.42 | 3.47 | 2.08 | 2.74 |
| Quick ratioi | 4.63 | 4.38 | 4.26 | 4.58 | 3.28 | 3.31 | 1.98 | 2.52 |
| Debt / assetsi | 30.68 | 33.87 | 40.17 | 33.73 | 60.59 | 51.31 | 67.59 | 54.32 |
| LT debt / equityi | 61.30 | 92.62 | 115.37 | 85.42 | 940.60 | 199.13 | 554.36 | 281.17 |
| Interest coveragei | -9.38 | -6.78 | -8.91 | -7.92 | -23.67 | -32.18 | -27.66 | -3.58 |
| Revenue CAGR (3Y) %i | 18.03 | 9.49 | 8.58 | -7.06 | -14.53 | -9.86 | 20.93 | 64.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -424.18 | -705.96 | -410.76 | -29.38 | -32.57 | -151.79 |
| ROA %i | -37.40 | -30.56 | -16.98 | -4.26 | -3.88 | -6.42 |
| ROIC %i | -50.70 | -40.49 | -23.53 | -6.00 | -5.17 | -8.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -78.49 | -47.27 | -17.73 | -7.85 | -6.46 | -9.74 |
| FCF / sales %i | -- | -- | -- | -- | -- | 2.56 |
| Current ratioi | 2.05 | 2.00 | 2.75 | 2.74 | 3.13 | 4.05 |
| Quick ratioi | 1.95 | 1.89 | 2.50 | 2.52 | 2.81 | 3.75 |
| Debt / assetsi | 72.97 | 71.96 | 61.23 | 54.32 | 59.02 | 77.17 |
| LT debt / equityi | 993.95 | 992.88 | 440.45 | 281.17 | 325.79 | 2,490.59 |
| Interest coveragei | -19.10 | -13.97 | -6.86 | -3.58 | -3.40 | -6.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- FILSPARI is the largest reported line at 83.19% of revenue, across 3 reported segments.
- The next-largest line, Tiopronin products, is a distant second at 11.96% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
FILSPARI83.19%
Tiopronin products11.96%
License and collaboration revenue4.85%
Quote time 2026-10-08 07:24:39 · For reference only, not investment advice and not tailored to your situation.